Resources & Guides

Retatrutide is not commercially available. Phase 3 results have been reported and Lilly plans a BLA filing in Q1 2027, with approval possible in 2027-2028. In the US, lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). Compounding pharmacies cannot lawfully supply it. Here is everything you need to know about retatrutide availability worldwide.

Unlike semaglutide and tirzepatide, compounded retatrutide is explicitly prohibited under federal law — there is no approved version, so the shortage exemption never applied. This guide explains the legal reality, what's actually in research-peptide vials, and what your real options are.

Retatrutide has no official price. It's still in Phase 3 clinical trials. This guide covers what people actually pay today for research peptides, why compounded retatrutide is not a lawful option, what it will likely cost at commercial launch, and how it compares to tirzepatide and semaglutide.

Retatrutide isn't FDA-approved yet. Lawful access is limited to clinical trials and, for a small group of adults with a BMI of 35 or more and two or more serious obesity-related complications whose obesity has not responded to the highest available dose of current treatment and who cannot join a trial, Lilly's expanded access program (requested by a physician). This guide covers how to join a trial, who qualifies for expanded access, why compounding pharmacies cannot lawfully supply retatrutide, and what research peptide vendors actually sell, plus what you need to know about safety, legality, and costs.